AVERETT DEVRON R 4
4 · ANADYS PHARMACEUTICALS INC · Filed May 31, 2005
Insider Transaction Report
Form 4
AVERETT DEVRON R
Chief Scientific Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2005-05-26−2,960→ 61,746 totalExercise: $6.88From: 2000-03-06Exp: 2010-03-05→ Common Stock (2,960 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2005-05-26−980→ 0 totalExercise: $6.88From: 2000-01-24Exp: 2010-01-23→ Common Stock (980 underlying) - Exercise/Conversion
Common Stock
2005-05-26$2.95/sh+241$711→ 11,680 total - Exercise/Conversion
Common Stock
2005-05-26$6.88/sh+980$6,742→ 6,273 total - Exercise/Conversion
Common Stock
2005-05-26$6.88/sh+2,960$20,365→ 9,233 total - Exercise/Conversion
Common Stock
2005-05-26$6.88/sh+2,206$15,177→ 11,439 total - Exercise/Conversion
Stock Option (Right to Buy)
2005-05-26−2,206→ 3,677 totalExercise: $6.88From: 2000-06-14Exp: 2010-06-13→ Common Stock (2,206 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2005-05-26−241→ 0 totalExercise: $2.95From: 2002-01-30Exp: 2011-01-29→ Common Stock (241 underlying)
Holdings
- 23,229(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]Includes 5,293 shares acquired pursuant to the Anadys Pharmaceuticals, Inc. 2004 Employee Stock Purchase Plan.
- [F2]All shares subject to the option have vested and are exercisable as of the date of this filing.